U.S., March 8 -- ClinicalTrials.gov registry received information related to the study (NCT06864572) titled '[68Ga]Ga-P17-079 in the Diagnosis and Treatment of Metastatic Prostate Cancer' on Feb. 19.
Brief Summary: Preclinical studies have confirmed that [68Ga]Ga-P17-079 in both mouse prostate tumors and osseogenic metastases has high uptake and prolonged retention, which enables [68Ga]Ga-P17-079 to be fully absorbed by the lesions, and it is possible to detect bone metastases, prostate cancer primary sites, lymph node metastases and organ metastases at the same time in a single examination. It is a potential "killing two birds with one stone" imaging agent. At this stage, the clinical study of [68Ga]Ga-P17-079 in the diagnosis and treatme...